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Abstract
Dilated cardiomyopathy (DCM) is a heterogeneous group of heart diseases with a strong genetic background. Currently,
many human DCM cases exist where no causative mutation can be identified. DCM also occurs with high prevalence in
several large dog breeds. In the Doberman Pinscher a specific DCM form characterized by arrhythmias and/or
echocardiographic changes has been intensively studied by veterinary cardiologists. We performed a genome-wide
association study in Doberman Pinschers. Using 71 cases and 70 controls collected in Germany we identified a genome-
wide significant association to DCM on chromosome 5. We validated the association in an independent cohort collected in
the United Kingdom. There is no known DCM candidate gene under the association signal. Therefore, DCM in Doberman
Pinschers offers the chance of identifying a novel DCM gene that might also be relevant for human health.
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Introduction
Cardiomyopathies are a heterogeneous group of diseases, which
can be inherited or associated with specific cardiac or systemic
disorders. Human primary cardiomyopathies are usually divided
into five main pathological groups: dilated, hypertrophic, restric-
tive, arrhythmogenic right ventricular, and unclassified cardiomy-
opathies [1]. They may be caused by one or several genetic
mutations. Alternatively cardiomyopathies may be idiopathic, or
secondary post-inflammatory, following a generalized systemic
disorder. In humans the prevalence of dilated cardiomyopathy
(DCM) is 36.5/100,000 [2]. Inherited forms make up to 35% of
the cases [3] and are mostly inherited as monogenic autosomal
dominant traits [4].
Dogs are excellent genetic models for human diseases as they
share many hereditary diseases with humans. Purebred dog breeds
represent isolated populations with extreme genetic bottlenecks at
breed foundation ,200 years ago. Therefore the heterogeneity
within a breed is greatly reduced, which facilitates the identifica-
tion of causative mutations for complex diseases [5,6]. Another
advantage of dogs as a model for DCM is that they can be
examined with sophisticated diagnostic equipment in a very
similar way to humans, so that the pathophysiological alterations
of the heart are relatively well understood.
Large dogs are frequently affected by cardiomyopathies and in
the Doberman Pinscher a specific form of DCM is known. The
Doberman DCM is inherited as an autosomal dominant trait
similar to most human DCM forms [7]. The prevalence of
Doberman DCM in Europe is 58.2% [8]. Electrical aberrations
like ventricular arrhythmias are typical for Doberman DCM and
occur together with or even before morphological changes of the
heart. Frequently, affected Doberman Pinschers suffer a sudden
death due to these arrhythmias and do not reach the stage where
they develop a congestive heart failure [9–12]. Age of onset can be
as early as one year, but eight year old dogs can also still develop
DCM. The average age at which DCM affected Dobermans
develop congestive heart failure is 6.7 years [9]. The progression of
Doberman DCM can be divided into 3 stages. In stage I, the
morphology of the heart is normal and there are no clinical signs of
heart disease or electrical derangements. However, a genetic defect
is assumed to exist, which gradually causes damage on the cellular
level. This stage can last for months or years. [13]. In stage II,
morphological and electrical changes occur, but there are still no
clinical signs of the heart disease. From the owner’s point of view,
there are no signs of DCM and the dog seems to be healthy.
Therefore, this stage is called ‘‘the occult stage’’. During Stage II
morphological and electrical abnormalities may coexist, or one form
may be predominant at any time. About 30% of the affected dogs
die due to sudden death in this stage, which typically lasts 3 to 4
years. Finally, affected dogs enter stage III, which is also called the
‘‘overt stage’’ of the Doberman DCM. Often, this is the first time
that the owners realize that their dogs may have heart problems.
[13,14]. In stage III, affected dogs develop congestive heart failure
and the typical clinical symptoms like tachycardia, tachypnea, and
cough. Stage III may last days to years until the dogs die due to
sudden death or as a result of the congestive heart failure [13,14].
In humans, mutations in at least different 19 genes may cause
hereditary forms of DCM [15,16]. Many of these genes encode
structural proteins of the heart muscle. However, there are still
many human DCM forms, where the causative mutation remains
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unknown. Using a comparative approach, many of the known
human genes and some functionally related genes were evaluated
in Dobermans. So far 15 genes (ACTC1, CAV1, CSRP3, DES,
LDB3, LMNA, MYH7, PLN, SGCD, TCAP, TNNC1, TNNI3,
TNNT2, TPM1, VCL) were studied, but did not reveal the
causative mutation for Doberman DCM [17–22]. Therefore, the
identification of the causative mutation of the Doberman DCM
might identify a novel DCM gene that is also relevant for human
DCM forms, where the causative mutations have not been
identified so far. In this study we used a hypothesis-free approach
and performed a genome-wide association study (GWAS) to map
genetic risk factors for DCM in Doberman Pinschers.
Results
Phenotypical characterization
We sampled Doberman Pinschers in Germany and the UK. We
compiled a discovery cohort consisting of 71 DCM affected and 70
DCM control dogs from Germany. All dogs in the discovery
cohort were examined by Holter electrocardiogram (24 hour
Figure 1. Genome-wide association mapping of Doberman DCM. (A) A case-control genome-wide allelic association analysis in the discovery
cohort showed a significant association of the phenotype arrhythmia in 62 cases and 70 controls to SNPs on chromosome 5. (B) Several SNPs in a
,7 Mb interval on chromosome 5 were associated. (C) The association of single SNPs (black) and haplotypes (red) at the DCM locus indicated that
the most likely position for the DCM risk factor is between 53 Mb and 54 Mb. Haplotypes were estimated with the Haploview software and the
‘‘confidence intervals’’ option. (D) As the dog genome annotation is still fragmentary, we inferred the gene content by extrapolating from the human
orthologous interval. The grey shaded area corresponds to the interval between 53 and 54 Mb on CFA 5.
doi:10.1371/journal.pone.0020042.g001
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ECG) and echocardiogram. DCM in Doberman Pinschers can
present with electrical derangements, such as arrhythmias that can
be monitored by the Holter electrocardiogram and/or with
morphological changes, such as a dilation of the heart that can be
seen by echocardiogram. Many Doberman Pinschers with DCM
show a combination of both symptoms. Our discovery cohort
consisted of 19 cases with isolated arrhythmias, 9 dogs with
isolated echocardiographic abnormalities, and 43 dogs with a
combination of arrhythmias and echocardiographic abnormalities.
The control group of the discovery cohort consisted of Doberman
Pinschers older than 6 years of age with normal Holter
electrocardiogram and normal echocardiographic findings. We
further collected a validation cohort consisting of 15 Doberman
DCM cases and 24 Doberman controls from the United
Kingdom. In the validation cohort one case had isolated
arrhythmias and 14 cases had a combination of arrhythmia and
echocardiographic changes.
Mapping of the genome-wide association
We genotyped 1749376 SNP markers in the discovery cohort
consisting of 71 DCM cases and 70 controls. After removing non-
informative markers and markers with low call rates, 759916
markers remained for the final analysis. The genomic inflation
factor was 1.07 indicating that the samples were only minimally
stratified. We initially performed a genome-wide allelic association
study with the DCM phenotype. We detected a genome-wide
significant association on canine chromosome 5 (CFA 5). The
best-associated SNP, TIGRP2P73097 (CFA5:g.53,941,386T.C),
showed a raw p-value of 8.3661028 and a genome-wide corrected
p-value of 0.0071. There were no significant associations on any of
the other chromosomes.
We then analyzed the association to either the echocardio-
graphic changes or the arrhythmias separately. For the echocar-
diographic changes we removed the 19 DCM cases with isolated
arrhythmias and compared the remaining 52 cases to the 70
controls. CFA5:g.53,941,386T.C remained the best-associated
SNP, but the genome-wide corrected p-value increased to 0.0503.
In the GWAS with respect to the arrhythmias we used 62 cases
and 70 controls. Using these cohorts the genomic inflation factor
slightly increased to 1.13. For the phenotype arrhythmia we
observed the most significant associations of all performed analyses
(Figure 1). Twelve SNPs within a 3.6 Mb interval on CFA 5 had
genome-wide corrected p-values of less than 0.05. The best-
associated SNP was again CFA5:g.53,941,386T.C. It had an
asymptotic raw p-value of 1.1761028 and a genome-wide
corrected p-value of 0.0013. The odds ratio at this SNP was
8.15 with a 95% confidence interval ranging from 3.64–18.24.
The frequency of the DCM-associated C-allele at
CFA5:g.53,941,386T.C varies among the different subpheno-
types (Table 1). It is highest among the group of Dobermans with
isolated arrhythmias and lower in Dobermans that have only
echocardiographic changes. However, these differences in allele
frequencies between the different DCM sub-phenotypes are not
statistically significant (Fisher’s exact test).
Validation of the association
We genotyped the 10 best-associated SNPs from the arrhythmia
GWAS also in the validation cohort (Table 2). In the validation
cohort 9 of these 10 markers had p-values of less than 0.05. When
analyzing the discovery cohort and validation cohort together the
best combined raw p-value was 7.04610210 for
CFA5:g.53,941,386T.C. The C-allele at this SNP is found more
frequently in DCM cases in the discovery and the validation
cohort.
The genotype frequencies at this SNP are displayed in figure 2.
Among the combined 86 DCM cases of both cohorts 41
Dobermans (48%) were either homozygous or heterozygous for
the risk-allele. However, the other 45 DCM cases (52%) were
homozygous for the protective allele. Among the combined 94
Doberman controls, only 9 dogs (10%) carried the risk-allele in
heterozygous state, and none of the controls was homozygous for
the risk-allele.
Positional candidate gene analysis
As the annotation of the canine genome is still far from perfect,
we inferred the gene content of a 3 Mb interval around the
association signal from the corresponding human interval
(Figure 1D). This interval corresponds to a segment from 58.0–
61.4 Mb on HAS 1. The human interval contains 14 annotated
genes and 4 hypothetical loci (NCBI MapViewer, build 37.2). A
careful inspection of these genes and database searches of their
presumed function revealed that none of them represents a known
DCM gene. The ‘‘FGGY carbohydrate kinase domain contain-
ing’’ gene (FGGY) in the associated interval is a protein coding gene
with unknown function. We sequenced its 15 coding exons in four
affected and four control Doberman Pinschers and compared the
sequences to the Boxer reference genome [23]. We identified 14
polymorphisms in total (Table S1). One variant was a silent
polymorphism in exon 10, the other 13 polymorphisms were
located in introns. At the exonic polymorphism all eight Dober-
man Pinschers were homozygous for the variant allele, whereas
the Boxer sequence represented the presumed wildtype allele. We
typed four intronic polymorphisms in the discovery cohort, but
their association was at least four orders of magnitudes weaker
than CFA5:g.53,941,386T.C.
Discussion
We detected a significant genome-wide association of several
SNPs on CFA 5 to DCM in Doberman Pinschers from Germany.
The association could be confirmed in an independent cohort of
Doberman Pinschers from the UK. Our findings confirm the value
of purebred dogs to elucidate genetic risk factors for complex
diseases. In humans DCM is extremely heterogeneous and very
large cohorts are required to detect associations to low frequency
risk alleles, while extremely rare risk alleles may not be detectable
at all in human genome-wide association studies [24]. Doberman
Pinschers represent a closed population that was founded about
150 years ago from a limited number of individuals by the German
Friedrich Louis Dobermann [25]. Due to their population history
the heterogeneity of DCM is much smaller in Doberman Pinschers
than in humans, which facilitates the genetic mapping of DCM
risk loci. However, even within the Doberman Pinscher breed,
DCM is not a simple monogenic trait where a single mutation with
Table 1. Frequency of the DCM-associated C-allele at
CFA5:g.53,941,386T.C in different subsets of the discovery
cohort.
Subset Dogs Allele Frequency [%]
Arrhythmia only 19 13/38 34.2%
Arrhythmia & echocardiographic
changes
43 28/86 32.6%
Echocardiographic changes only 9 2/18 11.1%
Control dogs 70 8/140 5.7%
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full penetrance is responsible for all cases. Our findings that
approximately half of the DCM affected Doberman Pinschers
carry the risk-allele on CFA 5 indicate that this is a major, but not
the only genetic risk factor for DCM in this breed. The lack of
other association signals further suggests that the unexplained 50%
DCM cases might be caused by several different genetic risk
factors of small effect size, which cannot be detected with the
currently available cohort sizes.
The recent genetic bottleneck in the Doberman Pinscher breed
is responsible for a relatively long-reaching linkage disequilibrium
(LD) in this breed. The long LD facilitates the detection of
causative mutations with a limited amount of markers. Unfortu-
nately, it simultaneously limits the mapping resolution. Thus the
true causative mutation underlying the detected association signal
might be located anywhere in a 1 Mb region, which poses
significant challenges for mutation identification, especially if the
causative variant should be a non-coding mutation. We already
excluded coding mutations of the FGGY gene.
Doberman DCM is characterized by two distinct clinical
features. On the one hand arrhythmias are very typical in
Doberman DCM and not seen so frequently in DCM forms of
other large dog breeds. On the other hand some Doberman
Pinschers with DCM present only with echocardiographic
changes, but no arrhythmia. The latter group more closely
resembles the clinical symptoms of DCM in other large dog breeds
such as the Irish Wolfhound, Great Dane, or Newfoundland. The
strong association to arrhythmia in our cohorts suggests that the
risk factor on CFA 5 is primarily related to the arrhythmias. On
the other hand, the weaker association of CFA 5 to echocardio-
graphic changes might indicate that the heart dilation is indeed
controlled by at least partially distinct genetic risk factors. The
genetic dissection of the two sub-phenotypes is hampered by the
fact that the majority of DCM affected Doberman Pinschers have
a combination of both symptoms of varying severity and with a
variable age of onset.
In conclusion, we have mapped a major genetic risk factor for
DCM in the Doberman Pinscher to CFA 5. In the region of the
association signal, no obvious DCM candidate genes are located.
Thus the further investigation of this association signal has a high
chance of identifying a new DCM gene that might also be of
relevance for a fraction of the unexplained human DCM cases.
Materials and Methods
Ethics statement
The dogs in this study were examined during preventive
diagnostic procedures with the consent of their owners. All local
regulations (Germany and UK) were strictly observed. The study
was approved by the University of Munich and the University of
Liverpool Committees on Research Ethics, respectively. There is
no permit number as this study is not based on an invasive animal
experiment. The data were obtained during diagnostic procedures
that would have been carried out anyway. This is a very special
situation in veterinary medicine. As the data are from client-
owned dogs that underwent normal veterinary exams, there was
Table 2. Validation of the 10 best-associated SNPs from the arrhythmia discovery cohort.
Genome-wide
analysis
Replication
analysis
Allele frequencies
(cases/controls)
Allele frequencies
(cases/controls)
Position SNP Alleles Germany (62/70) praw
a UK (15/24) praw
a
Combined p-
value
53,941,386 TIGRP2P73097 C/T 0.33/0.06 1.1761028 0.13/0.02 0.048 7.04610210
53,820,695 TIGRP2P73026 T/C 0.31/0.05 4.2761028 0.11/0.02 0.104 3.8761029
53,344,207 BICF2P586593 C/G 0.31/0.06 4.8761028 0.13/0.02 0.048 3.0661029
53,751,794 BICF2P1162831 A/C 0.31/0.06 6.7661028 0.13/0.02 0.048 4.4961029
53,252,611 BICF2S2334544 T/C 0.31/0.06 9.8461028 0.13/0.02 0.048 6.3261029
53,252,611 TIGRP2P72998 A/G 0.31/0.06 1.4361027 0.13/0.02 0.048 9.0961029
53,776,936 TIGRP2P73008 G/C 0.31/0.06 1.4361027 0.13/0.02 0.048 9.0961029
53,796,343 TIGRP2P73009 G/A 0.31/0.06 1.4361027 0.13/0.02 0.048 9.0961029
53,797,457 BICF2S23229423 A/G 0.31/0.06 1.4361027 0.20/0.02 0.007 2.1561029
54,816,226 BICF2P1307722 A/G 0.30/0.06 1.9761027 0.13/0.02 0.048 1.3061028
ap-values were calculated by x2 tests in an allelic association study.
doi:10.1371/journal.pone.0020042.t002
Figure 2. Genotype frequencies at the best associated SNP
TIGRP2P73097. The genotype distributions indicate a dominant or
additive effect of the disease-associated variant.
doi:10.1371/journal.pone.0020042.g002
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no ‘‘animal experiment’’ according to the legal definitions in
Germany and the UK. Nonetheless, the study was reviewed and
approved by the local ethics review boards.
Animals
We sampled 71 DCM affected Doberman Pinschers (40 males
and 31 females, mean age 7.9 years) and 70 unaffected Doberman
Pinschers (28 males and 42 females, mean age 9.3 years) from
Germany for the discovery cohort. Furthermore, we sampled 15
DCM affected Doberman Pinschers (10 males and 5 females,
mean age 7.2 years) and 24 control Doberman Pinschers (7 males
and 17 females, mean age 8.5 years) from the United Kingdom for
the validation cohort.
Cardiologic examinations
All dogs were examined without sedation in right and left lateral
recumbency, scanning through the dependent thoracic wall.
Echocardiographic examinations in Germany were performed
using a commercially available high frame rate ultrasound system
equipped with a 2.0/4.3 MHz probe (Vivid 7 dimension, GE
Medical Systems) with simultaneous ECG recording by the
ultrasound machine. Various echocardiographic machines with
simultaneous ECG were used in the UK. M-mode measurements
were obtained from the right parasternal long-axis view. All valves
were examined using color-Doppler. Velocities over the aortic and
pulmonary valves were measured using continuous wave Doppler
examinations and had to be below 2.2 m/sec. For the German
dogs 24 hour Holter recordings were performed at each exam and
analyzed using one of two commercially available software
programs (Custo tera, Arcon Systems GmbH; Amedtech ECGpro
Holter software, EP 810 digital Recorder, Medizintechnik Aue
GmbH). Manual adjustments and accuracy verification of the
arrhythmias recognized by the software were performed by
members (veterinarians) of the LMU cardiology team with
extensive experience in Holter analysis and overseen by a
Diplomate in cardiology (GW). Holter recordings were not
mandatory in the UK, but when used, the Del Mar Reynolds
Lifecard CF system (Del Mar Reynolds Medical Ltd. UK) was
used with analysis performed by one of two commercial companies
(LifeCorp USA or Holter Monitoring Services, UK).
Exclusion and inclusion criteria
We grouped dogs of the discovery cohort into the case and
control groups according to the results of the Holter and
echocardiographic M-mode examinations at the last available
examination:
Control group. Dogs in this group had to be older than 6
years of age, no clinical signs, ,50 ventricular premature
contractions (VPCs)/24 hours, and normal echocardiographic
measurements. M-mode values that were considered to be normal
were as follows: left ventricular internal end-diastolic dimension
(LVIDd)#47 mm and left ventricular internal end-systolic
dimension (LVIDs)#38 mm [14,26].
DCM case group. DCMwas diagnosed if either.100 VPCs/
24 hours were detected on Holter examination or if echocar-
diographic M-mode examinations were indicative for DCM, or both
(Holter and echocardiography) were abnormal. M-mode values that
were considered abnormal and indicative of DCM were as follows:
LVIDd$49 mm [27,28], or LVIDs$40 mm [13,14], or both
measurements increased.
Arrhythmia case group. Dogs with .100 VPCs/24 hours.
Dilation case group. Dogs with: LVIDd$49 mm or
LVIDs$40 mm, or both measurements increased.
Dogs with evidence of systemic disease, concomitant congenital
heart disease or evidence of primary mitral valve disease (based on
echocardiography) were not included. Dogs that had between 50
and 100 VPCs/24 hours were considered ‘‘equivocal’’ and were
also not included in the study.
Dogs in the validation control cohort were$7 years old, had
normal echocardiogram and no arrhythmias identified during
three minute electrocardiographic recording or during the
echocardiographic study but were not required to have a Holter
examination. The validation case cohort all had echocardiograph-
ic examinations, and 4/15 also had Holters with an additional 3
cases showing frequent ventricular premature complexes during
echocardiography and electrocardiography.
SNP genotyping
Genomic DNA was isolated from EDTA blood with the
Nucleon Bacc2 kit (GE Healthcare). The DNA was genotyped at
the Centre National de Ge´notypage, Evry, France using illumina
canine_HD chips containing 1749376 SNP markers. Genotypes
were stored in a BC/SNPmax Database version 3.4 (BC/
Platforms). Targeted genotypes were determined by Sanger
sequencing on an ABI 3730 capillary sequencer.
Genome sequences
Genome sequences were downloaded using the NCBI Map
Viewer genome browser [29]. The CanFam2.1 version of the dog
genome and build 37.2 of the human genome reference assembly
were used.
Mapping of the association
We used the plink software for the genome-wide association
analysis [30]. A total of 174,376 markers were initially considered
for the analysis. No individual was removed for low genotyping
success (–mind 0.1). After removing 1,911 SNPs which failed
missingness test (–geno 0.1) the average genotyping rate per
individual was 99.1%. A total of 97,382 SNPs had a minor allele
frequency of less than 10% and were removed (–maf 0.1). An
additional 778 markers that deviated from a relaxed Hardy-
Weinberg equilibrium based on HWE test (p,1610205) were also
excluded from further analysis. After frequency and genotyping
pruning, 75,916 SNPs remained in the analysis.
A case-control analysis using the option –assoc was applied.
Genome-wide corrected empirical p-values were determined
applying the max(T) permutation procedure implemented in plink
with 100,000 permutations (–mperm 100000). The genomic
inflation factor based on the median chi-squared was obtained
by applying the –adjust option.
During the fine-mapping single SNP associations and haplotype
associations were calculated with Haploview [31]. Haplotype blocks
were estimated using the ‘‘confidence intervals’’ option of Haploview.
DNA sequencing and mutation analysis
The exon/intron structure of the canine FGGY gene was
inferred by alignment of human mRNA sequence to the canine
genomic sequence. For mutation analysis, PCR products were
amplified from four DCM affected and four healthy control
Doberman Pinschers using AmpliTaq Gold 360 Master Mix
(Applied Biosystems). The PCR products were directly sequenced
after rAPid alkaline phosphatase (Roche) and exonuclease I (New
England Biolabs) treatment using both PCR primers with the ABI
BigDye Terminator Sequencing Kit 3.1 (Applied Biosystems) on
an ABI 3730 capillary sequencer. Sequence data were analyzed
with Sequencher 4.9 (GeneCodes).
DCM Association in Doberman Pinschers
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Supporting Information
Table S1 Polymorphisms and genotypes of 4 DCM affected and
4 control Doberman Pinschers in the FGGY gene.
(XLS)
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